Predictive factor for the response to adjuvant therapy with emphasis in breast cancer

por Munster, Pamela N, Norton, Larry
Publicado 2001

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead

por Tsang, Erica S, Munster, Pamela N
Publicado 2022

Host histone acetylation unlocks HDAC inhibitor potential

por Terranova-Barberio, Manuela, Thomas, Scott, Munster, Pamela N.
Publicado 2017

Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt

por Thomas, Scott, Thurn, K. Ted, Raha, Paromita, Chen, Stephanie, Munster, Pamela N.
Publicado 2013

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression

por Raha, Paromita, Thomas, Scott, Thurn, K Ted, Park, Jeenah, Munster, Pamela N
Publicado 2015

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay

por Block, Thaddeus S, Murphy, Tiffany I, Munster, Pamela N, Nguyen, Dat P, Lynch, Frank J
Publicado 2017

ATM-SPARK: A GFP phase separation–based activity reporter of ATM

por Li, Xiaoquan, Chung, Chan-I, Yang, JunJiao, Chaudhuri, Sibapriya, Munster, Pamela N., Shu, Xiaokun
Publicado 2023

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid...

por Pivonello, Rosario, Munster, Pamela N., Terzolo, Massimo, Ferrigno, Rosario, Simeoli, Chiara, Puglisi, Soraya, Bali, Utsav, Moraitis, Andreas G.
Publicado 2022

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.

por Vesole, David H., Berdeja, Jesus, Matous, Jeffrey, Trudel, Suzanne, Schade, Henning, Munster, Pamela, Berkeley, Savannah, Sun, Benjamin, Martin, Tom
Publicado 2023

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

por De Souza, Andre, Tavora, Fabio A., Mahalingam, Devalingam, Munster, Pamela N., Safran, Howard P., El-Deiry, Wafik S., Carneiro, Benedito A.
Publicado 2020

HDAC inhibition potentiates immunotherapy in triple negative breast cancer

por Terranova-Barberio, Manuela, Thomas, Scott, Ali, Niwa, Pawlowska, Nela, Park, Jeenah, Krings, Gregor, Rosenblum, Michael D., Budillon, Alfredo, Munster, Pamela N.
Publicado 2017

A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models

por Thomas, Scott, Roche, Elysia, Desai, Pujan, Pawlowska, Nela, Bauer, Diana, Gingrich, David, Hsu, Emily, Deitchman, Amelia N., Aweeka, Fran, Munster, Pamela N.
Publicado 2023

Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer

por Park, Jeenah, Thomas, Scott, Zhong, Allison Y., Wolfe, Alan R., Krings, Gregor, Terranova-Barberio, Manuela, Pawlowska, Nela, Benet, Leslie Z., Munster, Pamela N.
Publicado 2018

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (...

por Anders, Carey, Munster, Pamela, Northfelt, Donald, Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Sachdev, Jasgit C
Publicado 2019

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

por Sachdev, Jasgit C., Munster, Pamela, Northfelt, Donald W., Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Thiagalingam, Arunthathi, Anders, Carey
Publicado 2020

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

por Odia, Yazmin, Cavalcante, Ludimila, Safran, Howard, Powell, Steven Francis, Munster, Pamela N, Ma, Wen Wee, Carneiro, Benedito A, Bastos, Bruno R, Mikrut, Stacy, Mikrut, William, Giles, Francis J, Sahebjam, Solmaz
Publicado 2022

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

por Tsang, Erica S., Aggarwal, Rahul R., Dhawan, Mallika S., Bergsland, Emily K., Alvarez, Edwin A., Calabrese, Susan, Pacaud, Romain, Garcia, Jose, Fattah, Delaire, Thomas, Scott, Grabowsky, Jennifer, Moasser, Mark M., Munster, Pamela N.
Publicado 2022

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

por Terranova-Barberio, Manuela, Pawlowska, Nela, Dhawan, Mallika, Moasser, Mark, Chien, Amy J., Melisko, Michelle E., Rugo, Hope, Rahimi, Roshun, Deal, Travis, Daud, Adil, Rosenblum, Michael D., Thomas, Scott, Munster, Pamela N.
Publicado 2020

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

por Munster, Pamela N., Greenstein, Andrew E., Fleming, Gini F., Borazanci, Erkut, Sharma, Manish R., Custodio, Joseph M., Tudor, Iulia Cristina, Pashova, Hristina I., Shepherd, Stacie Peacock, Grauer, Andreas, Sachdev, Jasgit C.
Publicado 2022

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation st...

por Munster, Pamela, Krop, Ian E., LoRusso, Patricia, Ma, Cynthia, Siegel, Barry A., Shields, Anthony F., Molnár, István, Wickham, Thomas J., Reynolds, Joseph, Campbell, Karen, Hendriks, Bart S., Adiwijaya, Bambang S., Geretti, Elena, Moyo, Victor, Miller, Kathy D.
Publicado 2018